Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 3/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10650846 | 1.00 | MEN1 (0.44) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL17711236 | 0.96 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL31487414 | 0.96 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL8759341 | 0.96 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL8759336 | 0.96 | MEN1 (0.47) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL29496543 | 0.92 | MEN1 (0.44) | MEN1KMT2APRCPDPP7CTSC | |
| Trifluoroacetic Acid SCHEMBL29808681 | 0.90 | MEN1 (0.43) | MEN1KMT2APRCPDPP7CTSC | |
| SCHEMBL30973948 | 0.89 | MEN1 (0.42) | MEN1KMT2APRCPDPP7 | |
| SCHEMBL30745230 | 0.88 | MEN1 (0.41) | MEN1KMT2APRCPDPP7EPHX2 | |
| SCHEMBL30712166 | 0.88 | MAPK8 (0.43) | MEN1KMT2APRCPDPP7CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | OHIO STATE INNOVATION FOUNDATION | 2024-10-31 | — | — | US | disclosed |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| EP-4079316-A1 | PROCOAGULANT COMPOUNDS | Bioverativ Therapeutics Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2022-09-29 | — | — | US | disclosed |
| US-20220243189-A1 | PROCOAGULANT COMPOUNDS | BIOGEN MA INC. | 2022-08-04 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3693000-B1 | PROCOAGULANT COMPOUNDS | BIOVERATIV THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MEN1 1026/4885KMT2A 4874/4885PRCP 20/4885 |
| US-11352394-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | VIP, LNPEP, IAPP | MEN1 1156/4885KMT2A 4734/4885PRCP 55/4885 |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | SLC3A2, SPPL2B, SLC7A1 | MEN1 2390/4885KMT2A 3834/4885PRCP 234/4885 |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | MEN1 2122/4885KMT2A 4814/4885PRCP 34/4885 |
| US-20240245790-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | MEN1 2122/4885KMT2A 4814/4885PRCP 34/4885 |
| US-20260008812-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC38A7, SLC7A1, SLC6A7 | MEN1 2105/4885KMT2A 4004/4885PRCP 140/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | MEN1 1825/4885KMT2A 4214/4885PRCP 349/4885 |
| US-20220243189-A1 | PROCOAGULANT COMPOUNDS | PLG, F2, PLAT | MEN1 1483/4885KMT2A 3722/4885PRCP 18/4885 |
| US-20220306693-A1 | CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF | CHN2, TAP2, VIP | MEN1 1607/4885KMT2A 4570/4885PRCP 138/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | MEN1 4713/4885KMT2A 2819/4885PRCP 522/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MEN1 1026/4885KMT2A 4874/4885PRCP 20/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MEN1 1818/4885KMT2A 4374/4885PRCP 332/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | MEN1 2232/4885KMT2A 3978/4885PRCP 279/4885 |
| US-20260001916-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | MEN1 2246/4885KMT2A 3758/4885PRCP 330/4885 |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | CHN2, TAP2, VIP | MEN1 1607/4885KMT2A 4570/4885PRCP 138/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | MEN1 1338/4885KMT2A 4698/4885PRCP 102/4885 |
| US-20240360174-A1 | CELL-PENETRATING PEPTIDE SEQUENCES | VIP, LNPEP, NGLY1 | MEN1 896/4885KMT2A 4852/4885PRCP 24/4885 |
| US-11987647-B2 | Cyclic cell-penetrating peptides with one or more hydrophobic residues | VIP, LNPEP, TAP1 | MEN1 1405/4885KMT2A 4790/4885PRCP 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.